An observational study in Behçet Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Behcet Syndrome by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · Assiut University.
Among the 18 studies in Behcet Syndrome by Assiut University, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2026, is one of 14 observational ones, and was the 18th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →6 of the 18 studies in Behcet Syndrome by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 20–45
Assiut University
Ages 20–45
Assiut University
Ages 19–60 · Healthy volunteers
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 90 across 63 observational studies indexed under Behcet Syndrome.
Median enrollment 35 across the 4 interventional studies, 77 across the 14 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Behcet Syndrome by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07845162Assiut UniversitySerum EBI-3 Protein Levels in Behçet's Disease | 2027-09-26 |
| NCT07803198Assiut UniversityAsprosin in Behect Patients | 2027-09-30 |
| NCT07157189Assiut UniversityClinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Behcet Syndrome by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.
Behçet's disease is a chronic multisystem inflammatory disorder. Serum EBI-3 protein levels may reflect inflammatory activity.
This observational study will include adult patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease and age-matched healthy controls. Serum EBI-3 protein levels will be measured by ELISA.
Adult patients with Behçet's disease attending the Physical Medicine, Rheumatology and Rehabilitation Department at Assiut University Hospitals, and healthy controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease.
Age-matched healthy individuals without autoimmune or inflammatory diseases.
Mean serum EBI-3 protein level
Mean serum Epstein-Barr virus-induced gene 3 (EBI-3) protein concentration measured by ELISA in patients with Behçet's disease compared with healthy controls.
Time frame: Baseline
Serum EBI-3 level according to disease activity
Mean serum EBI-3 protein concentration according to Behçet's Disease Current Activity Form (BDCAF) score.
Time frame: Baseline
Serum EBI-3 level in patients with vascular involvement
Mean serum EBI-3 protein concentration in patients with and without vascular involvement
Time frame: Baseline
Serum EBI-3 level in patients with ocular involvement
Mean serum EBI-3 protein concentration in patients with and without ocular involvement.
Time frame: Baseline
Serum EBI-3 level in patients with neurological involvement
Mean serum EBI-3 protein concentration in patients with and without neurological involvement.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.